.svg){kind=small}
Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development.Join us at the 23rd AGAH Annual Meeting taking place 13-14 March 2014 in Munich, Germany. Discussions will take into account the impact of nonclinical findings, biopharmaceutics, personalised medicine approaches, updates on safety/tolerability from a clinical pharmacology perspective, as well as early investigation of lack of efficacy.View program and register online
-min.jpg)
.jpg)
Latest news
Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director
August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read moreRed4Research Blog – Alan’s Story
June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
